Polyphotonix
Noctura 400 (non-invasive, home based treatment for Diabetic Retinopathy)
- Funding £999,784
- Competition Phase 3 Competition
- Competition Date Spring 2015
- Local AHSN North East & North Cumbria AHSN
- Website http://www.polyphotonix.com/
- Key Contact Martin Holland
- Status On Market
- Pathways Diabetes
-
Technology Medical Devices
The Phase 3 project has been the catalyst for Noctura 400 (non-invasive, home based treatment for Diabetic Retinopathy) evaluation within the NHS. It has also initiated complimentary evaluation for early stage disease intervention in a primary care Optometry setting. Noctura 400 exposure has been increased as a result and as such has stimulated significant adoption interest from both patient groups and eye care professionals.
Comments are closed.